海王生物(000078) - 2023 Q1 - 季度财报

Financial Performance - Total operating revenue for Q1 2023 was CNY 9,957,850,383.56, an increase of 8.22% compared to CNY 9,201,630,764.82 in the same period last year[13] - Net profit attributable to shareholders was CNY 74,530,706.41, reflecting a growth of 5.08% from CNY 70,927,976.38 year-on-year[17] - The company reported a net profit of 110,250,475.24, an increase from 100,718,458.35 in the previous period, representing a growth of approximately 1.57%[35] - The company’s total comprehensive income attributable to shareholders was 74,530,706.41, compared to 70,927,976.38 in the previous period, indicating an increase of approximately 5.67%[36] - The company’s basic earnings per share were reported at 0.0271, compared to 0.0269 in the previous period, indicating a slight increase of about 0.74%[36] Cash Flow - Net cash flow from operating activities decreased by 34.79% to CNY 109,477,986.68, down from CNY 167,896,816.35 in the previous year[17] - Cash flow from investing activities decreased by 249.18%, primarily due to increased payments for pending equity[19] - The cash inflow from operating activities totaled CNY 9,793,709,617.80, an increase of 3.2% compared to CNY 9,490,023,016.36 in the previous period[46] - The cash outflow for investing activities was CNY 66,072,237.86, compared to CNY 54,382,937.71 in the previous period, resulting in a net cash flow from investing activities of -CNY 52,475,489.73, worsening from -CNY 15,028,363.89[47] - The cash inflow from financing activities reached CNY 5,061,920,115.16, an increase of 26% from CNY 4,019,349,217.88 in the previous period[47] - The net cash flow from financing activities improved to CNY 121,377,969.99, compared to a negative CNY 599,688,019.97 in the same period last year[47] - The total cash and cash equivalents at the end of the period were CNY 1,140,882,786.80, significantly up from CNY 533,008,970.87 at the end of the previous period[47] Assets and Liabilities - The company's total assets increased by 1.31% to CNY 36,728,073,881.49 from CNY 36,252,275,970.38 at the end of the previous year[17] - The total liabilities amounted to 30,562,048,972.47, compared to 30,141,845,242.23 in the previous period, indicating an increase of about 1.39%[33] - The total equity attributable to shareholders reached 4,755,846,194.56, up from 4,690,953,764.63, reflecting a growth of approximately 1.39%[33] - Current assets rose to ¥32,051,719,445.36, up from ¥31,524,548,826.78, indicating an increase of about 1.67%[57] - Short-term borrowings increased to ¥11,979,237,816.28 from ¥11,410,259,205.03, representing a growth of approximately 4.98%[57] - Accounts payable increased to ¥7,976,771,100.23 from ¥7,912,296,527.04, showing an increase of about 0.81%[57] - Other payables decreased to ¥6,176,220,199.51 from ¥6,288,109,695.49, reflecting a decline of approximately 1.78%[57] Expenses - The company’s research and development expenses were 11,339,139.83, slightly decreased from 11,543,209.87, showing a reduction of about 1.77%[35] - The sales expenses increased to 419,809,578.57 from 381,096,502.80, marking an increase of approximately 10.14%[35] - The company reported a 71.64% increase in income tax expenses, attributed to increased profitability of certain subsidiaries[19] Investments - Investment income rose by 304.05% due to gains from the disposal of subsidiaries[11] - The company reported a 686.58% increase in gains from asset disposals compared to the previous period, primarily due to increased fixed asset disposals by subsidiaries[50] - Construction in progress increased by 32.52% compared to the beginning of the year, mainly due to investments in subsidiary projects[19] - Long-term equity investments rose to ¥214,768,033.04 from ¥212,440,678.49, indicating a growth of about 1.09%[57] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 145,957[56] - The company received CNY 584,426.56 in tax refunds, a decrease of 82.1% from CNY 3,265,018.90 in the previous period[46]